Literature DB >> 33685889

In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.

Dae Hun Kim1, Su-Young Kim1, Hee Jae Huh2, Nam Yong Lee2, Won-Jung Koh1, Byung Woo Jhun3.   

Abstract

We evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs against all NTM species, including Mycobacterium avium complex, M. abscessus, and M. kansasii Rifabutin also had effective in vitro activity against macrolide- and aminoglycoside-resistant NTM isolates. Rifabutin could be worth considering as a therapeutic option for NTM disease, particularly drug-resistant disease.
Copyright © 2021 American Society for Microbiology.

Entities:  

Year:  2021        PMID： 33685889      PMCID： PMC8092860          DOI： 10.1128/AAC.02611-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex.

Authors:  Aristine Cheng; Yi-Tzu Tsai; Shu-Yuan Chang; Hsin-Yun Sun; Un-In Wu; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.

Authors:  Seong Mi Moon; Hye Yun Park; Su-Young Kim; Byung Woo Jhun; Hyun Lee; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.

Authors:  Enrico Tortoli; Thomas A Kohl; Barbara A Brown-Elliott; Alberto Trovato; Sylvia Cardoso Leão; Maria Jesus Garcia; Sruthi Vasireddy; Christine Y Turenne; David E Griffith; Julie V Philley; Rossella Baldan; Silvia Campana; Lisa Cariani; Carla Colombo; Giovanni Taccetti; Antonio Teri; Stefan Niemann; Richard J Wallace; Daniela M Cirillo
Journal:  Int J Syst Evol Microbiol       Date:  2016-08-04       Impact factor: 2.747

Review 5.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

6.  Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Authors:  Jotam G Pasipanodya; Deborah Ogbonna; Beatriz E Ferro; Gesham Magombedze; Shashikant Srivastava; Devyani Deshpande; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007-2016.

Authors:  Hyewon Lee; Woojae Myung; Won-Jung Koh; Seong Mi Moon; Byung Woo Jhun
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

9.  Rifabutin Is Active against Mycobacterium abscessus in Mice.

Authors:  Thomas Dick; Sung Jae Shin; Won-Jung Koh; Véronique Dartois; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

10.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139
View more
  2 in total

1.  In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria.

Authors:  Huiwen Zheng; Yiting Wang; Wencong He; Feina Li; Hui Xia; Bing Zhao; Shengfen Wang; Chen Shen; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.938

2.  Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.

Authors:  Uday S Ganapathy; Tian Lan; Philipp Krastel; Marissa Lindman; Matthew D Zimmerman; HsinPin Ho; Jansy P Sarathy; Joanna C Evans; Véronique Dartois; Courtney C Aldrich; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.